

Remarks

The foregoing amendments are made to insert and/or correct required errors in the Sequence Listing to make SEQ ID NO:34 in the Sequence Listing match SEQ ID NO:34 in the specification. Accordingly, Applicants respectfully request entry of the sequence listing submitted herewith under 37 C.F.R. §§ 1.821-1.825, which submission contains no new matter.


Applicants respectfully request that the present amendments be entered prior to further examination of the instant application.

Applicants believe that the present application is now in conditions for allowance which is respectfully requested. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: March 1, 2011

By: 
Belinda M. Lew
Registration No.53,212

CUSTOMER NUMBER 044638
AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.754.4230
Facsimile: 858.552.1936